Skip to Content
Merck
CN
  • Airway derived emphysema-specific alveolar type II cells exhibit impaired regenerative potential in COPD.

Airway derived emphysema-specific alveolar type II cells exhibit impaired regenerative potential in COPD.

The European respiratory journal (2024-08-16)
Yan Hu, Qianjiang Hu, Meshal Ansari, Kent Riemondy, Ricardo Pineda, John Sembrat, Adriana S Leme, Kenny Ngo, Olivia Morgenthaler, Kellie Ha, Bifeng Gao, William J Janssen, Maria C Basil, Corrine R Kliment, Edward Morrisey, Mareike Lehmann, Christopher M Evans, Herbert B Schiller, Melanie Königshoff
ABSTRACT

Emphysema, the progressive destruction of gas exchange surfaces in the lungs, is a hallmark of chronic obstructive pulmonary disease (COPD) that is presently incurable. This therapeutic gap is largely due to a poor understanding of potential drivers of impaired tissue regeneration, such as abnormal lung epithelial progenitor cells, including alveolar type II (ATII) and airway club cells. We discovered an emphysema-specific sub-population of ATII cells located in enlarged distal alveolar sacs, termed asATII cells. Single cell RNA-seq and in situ localisation revealed that asATII cells co-express the alveolar marker surfactant protein C (SPC) and the club cell marker secretaglobin-3A2 (SCGB3A2). A similar ATII sub-population derived from club cells was also identified in mouse COPD models using lineage labeling. Human and mouse ATII sub-populations formed 80-90% fewer alveolar organoids than healthy controls, indicating reduced progenitor function. Targeting asATII cells or their progenitor club cells could reveal novel COPD treatment strategies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Tamoxifen, ≥99%
Sigma-Aldrich
Donkey Anti-Chicken IgY Antibody, FITC conjugate, Species Adsorbed, Chemicon®, from donkey
Sigma-Aldrich
Anti-Prosurfactant Protein C (proSP-C) Antibody, serum, Chemicon®